Close Menu

Interpace Biosciences

In December, the company effected a 1-for-10 reverse stock split in order to help regain compliance with Nasdaq's minimum closing bid requirement.

The company said it will use the proceeds for working capital, repayment of indebtedness, and general corporate purposes.

Certain investors have agreed to buy 375,000 shares of Interpaces common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share. 

Interpace hopes to keep its stock listed on the Nasdaq as a result of the reverse split. 

A single institutional investor will purchase 2 million shares of Interpace's common stock and 1.6 million prefunded warrants to purchase its common stock. 

The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.

The company said in a filing with the US Securities and Exchange Commission that it is not in compliance with the exchange's minimum shareholders' equity requirement.

Contributing to the revenue increase was a rise in in test and collection volume for its thyroid cancer diagnostics.

The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.

The company attributed the revenue growth in part to increased reimbursement for its ThyraMir and ThyraGenX thyroid cancer tests.

Pages

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.